AstraZeneca (AZ) and its biologics R&D arm ... in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in ...

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities ...

“AstraZeneca’s expanded savings programs build ... significantly impact the lives of those suffering from asthma and COPD, providing them with an opportunity for improved health and quality ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy of available treatments ...

Among individuals with preserved ratio impaired spirometry, having interstitial lung abnormalities is associated with an ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.

There are also several drugs in development that target the imbalance in protease/antiprotease activity thought to result in alveolar enlargement seen in COPD, such as AstraZeneca's discovery ...

Bạch Mai Hospital and AstraZeneca signed a cooperation agreement on expanding collaboration in scientific research, medical ...

Breztri, a treatment for chronic obstructive pulmonary disease (COPD), came short of blockbuster status for AstraZeneca last year with sales of $978 million, but they were up by 44% compared to 2023.

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy of available treatments.